Exemestane experience in breast cancer treatment

Miller, 1989, Aromatase inhibition in the treatment of advanced breast cancer, Cancer Treat. Rev., 16, 83, 10.1016/0305-7372(89)90012-1 Brodie, 1981, Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo, Steroids, 38, 693, 10.1016/0039-128X(81)90087-8 Thürlimann, 1995, First line fadrozole HCl (CGS 16949A) versus tamoxifen (TAM) in advanced breast cancer: prospective randomised study SAKK 20/88, ASCO Abstr., 90, 98 Iveson, 1993, Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer, Cancer Res., 53, 266 Johnston, 1994, Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer, Cancer Res., 54, 5875 Dowsett, 1989, Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients, Cancer Res., 49, 1306 Dowsett, 1992, An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients, Eur. J. Cancer, 28, 415, 10.1016/S0959-8049(05)80065-6 MacNeill, 1995, The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in postmenopausal breast cancer patients, Cancer Chemother. Pharmacol., 36, 249, 10.1007/BF00685855 di Salle, 1994, Novel aromatase and 5alpha-reductase inhibitors, J. Steroid Biochem. Molec. Biol., 49, 289, 10.1016/0960-0760(94)90270-4 di Salle, 1990, Novel irreversible aromatase inhibitors, Ann. N.Y. Acad. Sci., 595, 357, 10.1111/j.1749-6632.1990.tb34309.x Buzzetti, 1993, Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione), Steroids, 58, 527, 10.1016/0039-128X(93)90029-M Giudici, 1988, 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor, J. Steroid Biochem., 30, 391, 10.1016/0022-4731(88)90129-X di Salle, 1990, 4-Aminoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione, J. Steroid Biochem. Molec. Biol., 37, 369, 10.1016/0960-0760(90)90486-5 Zaccheo, 1989, Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone, Cancer Chemother. Pharmacol., 25, 95, 10.1007/BF00692346 Zaccheo, 1991, Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours, Eur. J. Cancer, 27, 1145, 10.1016/0277-5379(91)90313-3 Evans, 1992, Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women, Cancer Res., 52, 5933 Zilembo, 1995, Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor, Br. J. Cancer, 72, 1007, 10.1038/bjc.1995.451 Johannessen D. C., Engan T., di Salle E., Zurlo M. G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S. and Lønning P. E.: Endocrine and clinical effects of exemestane (PNU 155071) a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients; Phase I study. Clin. Cancer Res., in press. di Salle, 1994, Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304), 303 Cocchiara, 1994, Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers, J. Endocr. Invest., 17, 78 Santen, 1980, Resistance of the ovary to blockade of aromatisation with aminoglutethimide, J. Clin. Endocr. Metab., 51, 473, 10.1210/jcem-51-3-473 Dowsett, 1992, Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients, J. Steroid Biochem. Molec. Biol., 43, 155, 10.1016/0960-0760(92)90201-S Harris, 1982, Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer, J. Clin. Endocr. Metab., 55, 718, 10.1210/jcem-55-4-718 Lønning, 1995, Mechanisms of action of endocrine treatment in breast cancer, Crit. Rev. Oncol./Haematol., 21, 158, 10.1016/1040-8428(94)00172-3 Jonat, 1996, A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer, Eur. J. Cancer, 32A, 404, 10.1016/0959-8049(95)00014-3 Dombernowsky, 1996, Double-blind trial in post-menopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effects and superiority of 2.5 mg letrozole over megestrol acetate (MA) Abstr. 64, ASCO Abstr., 15, 100 Elomaa, 1986, Aminoglutethimide as second-line therapy in advanced breast cancer, Breast Cancer Res. Treat., 7, S51 Geisler, 1996, Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects, Eur. J. Cancer, 32, 789, 10.1016/0959-8049(95)00623-0 Zambetti, 1987, Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments, Tumori, 73, 369, 10.1177/030089168707300409 Iveson, 1993, Response to third-line endocrine treatment for advanced breast cancer, Eur. J. Cancer, 29A, 572, 10.1016/S0959-8049(05)80154-6 Garcia-Giralt, 1992, Second and third line hormontherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medrozyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen, Breast Cancer Res. Treat., 24, 139, 10.1007/BF01961246 Murray, 1995, Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer, Breast Cancer Res. Treat., 35, 249, 10.1007/BF00665976